Skip to content

CryoPort, Inc. CYRX Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

BioLife Solutions logo
BioLife SolutionsBLFS
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE

Other financials

Income statement

See full
Revenue$47.8M+16.5%
Gross profit$21.9M+17.6%
Operating income-$9.6M-33.6%
Net income-$10.5M+12.0%
EPS (diluted)-$0.25+10.7%

Balance sheet

See full
Cash & equivalents$272.9M+656%
Total debt$230.7M+293%
Total equity$495.0M+24.1%
Total assets$763.6M+9.1%

Cash flow

See full
Operating cash flow$3.7M+186%
CapEx$10.0M+215%
Free cash flow-$6.2M+16.8%

Valuation

See full
Market cap$800.39M+151%
Enterprise value$758.23M+122%
P/E10.6×
P/S4.4×+2.4×

Profitability

See full
Gross margin47.2%+1.6pp
Operating margin-21.4%-8.8pp
Net margin39.2%+22.1pp
FCF margin-13%-3.6pp

Returns & leverage

See full
Return on equity14.5%+8.6pp
Debt / equity0.5×+0.3×
Current ratio2.1×-3.5×

Where this comes from

Reported directly by CryoPort, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: CryoPort, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CryoPort, Inc.'s payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CryoPort, Inc.'s payments to acquire intangible assets?
CryoPort, Inc. (CYRX) reported payments to acquire intangible assets of $301K in Q1 2026.
How has CryoPort, Inc.'s payments to acquire intangible assets changed year-over-year?
CryoPort, Inc.'s payments to acquire intangible assets decreased by 15.2% year-over-year, from $355K to $301K.
What is the long-term trend for CryoPort, Inc.'s payments to acquire intangible assets?
Over 4 years (2021 to 2025), CryoPort, Inc.'s payments to acquire intangible assets has grown at a 48.3% compound annual growth rate (CAGR), from $255K to $1.23M.